Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 Versus Placebo as Part of a Treatment Regimen Including Peginterferon α-2a (Pegasys) and Ribavirin (Copegus) or Peginterferon α-2b (PegIntron) and Ribavirin (Rebetol) in Treatment-naïve, Genotype 1, Hepatitis C-infected Subjects

Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 Versus Placebo as Part of a Treatment Regimen Including Peginterferon α-2a (Pegasys) and Ribavirin (Copegus) or Peginterferon α-2b (PegIntron) and Ribavirin (Rebetol) in Treatment-naïve, Genotype 1, Hepatitis C-infected Subjects

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Simeprevir (Primary) ; Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms QUEST-2
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 09 Apr 2015 According to a Janssen Sciences media release, a multivariate analysis of this study will be presented at the European Associate for the Study of the Liver (EASL) 2015.
    • 10 Oct 2014 A post-hoc analysis of pooled efficacy data from QUEST 1 and 2 was presented at the Viral Hepatitis Congress (VHC).
    • 13 Apr 2014 Pooled subgroup analysis of European patients presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top